Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
ESMO 2022: MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy | npj Breast Cancer
![PDF] MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1b7bbed1ac97b7cd7e1722645a4773fc21e58df3/3-Figure1-1.png "PDF] MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer | Semantic Scholar")
PDF] MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer | Semantic Scholar
Gaining Further Perspective into Treatment of Advanced Breast Cancer with CDK4/6 Inhibitors - The Medical Xchange
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer | Breast Cancer
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant | Breast Cancer Research | Full Text
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Carlo Palmieri (@cancermedic) / X
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer | Future Oncology
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal
MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange
MONARCH 3: OS Update - Slideset Download - ESMO Congress Paris | CCO
Abemaciclib regimen shows further signs of benefit in advanced breast cancer subgroup
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials - Toi - 2021 - Cancer Science - Wiley Online Library
Journal of Clinical Oncology on X: "MONARCH 3 trial: Abemaciclib as initial therapy for advanced breast cancer https://t.co/YlEshSmVC7 #bcsm https://t.co/3hGY4XRWHd" / X
Verzenio® + Fulvestrant | Efficacy | Verzenio (abemaciclib)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. | Semantic Scholar
Kaplan–Meier curve for overall survival in the premenopausal population... | Download Scientific Diagram
Abemaciclib plus aromatase inhibitor in advanced breast cancer
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Progression-free survival. PFS analysis at the February 14, 2017 data... | Download Scientific Diagram
Carlo Palmieri on X: "MONARCH 3 Final Overall Survival: No statistical improvement in OS ❌ but OS was improved by median 13 month favouring abemaciclib arm. Data for ribociclib/MONALEESA-2 shown for comparison
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Archive | ESMO
MONARCH 3: Overall Survival Results of Abemaciclib Plus Nonsteroidal AI for HR+/HER2− Advanced Breast Cancer | PracticeUpdate
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
Overall survival between matched MONARCH 1 and real-world chemotherapy... | Download Scientific Diagram
